Novel glutamine antagonists and uses thereof
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F22%3A00580592" target="_blank" >RIV/61388963:_____/22:00580592 - isvavai.cz</a>
Výsledek na webu
<a href="https://worldwide.espacenet.com/patent/search/family/065994832/publication/EP3692015B1?q=EP3692015B1" target="_blank" >https://worldwide.espacenet.com/patent/search/family/065994832/publication/EP3692015B1?q=EP3692015B1</a>
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Novel glutamine antagonists and uses thereof
Popis výsledku v původním jazyce
Glutamine antagonists and their use for treating oncological, immunological, and neurological diseases are disclosed. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder, the method comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof. Also disclosed are methods of enhancing the effects of an immune checkpoint inhibitor, enabling a subject to respond to an immune checkpoint inhibitor, or enabling the toxicity or the dose or number of treatments with an immune checkpoint inhibitor to be reduced, comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof, and an immune checkpoint inhibitor. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder that is refractory to checkpoint inhibitor therapy, the method comprising administering to a subject in need thereof, and having the refractory disease or disorder, a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof.
Název v anglickém jazyce
Novel glutamine antagonists and uses thereof
Popis výsledku anglicky
Glutamine antagonists and their use for treating oncological, immunological, and neurological diseases are disclosed. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder, the method comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof. Also disclosed are methods of enhancing the effects of an immune checkpoint inhibitor, enabling a subject to respond to an immune checkpoint inhibitor, or enabling the toxicity or the dose or number of treatments with an immune checkpoint inhibitor to be reduced, comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof, and an immune checkpoint inhibitor. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder that is refractory to checkpoint inhibitor therapy, the method comprising administering to a subject in need thereof, and having the refractory disease or disorder, a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof.
Klasifikace
Druh
P - Patent
CEP obor
—
OECD FORD obor
10401 - Organic chemistry
Návaznosti výsledku
Projekt
<a href="/cs/project/LTAUSA18166" target="_blank" >LTAUSA18166: Nádorově cílená proléčiva glutaminových antagonistů</a><br>
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2022
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Číslo patentu nebo vzoru
EP3692015
Vydavatel
EPO_1 -
Název vydavatele
European Patent Office
Místo vydání
Munich, The Hague, Berlin, Vienna, Brussels
Stát vydání
—
Datum přijetí
24. 8. 2022
Název vlastníka
The Johns Hopkins University - Ústav organické chemie a biochemie AV ČR, v. v. i
Způsob využití
B - Výsledek je využíván orgány státní nebo veřejné správy
Druh možnosti využití
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence